

# Constitutively Active Mutants of the Histamine H<sub>1</sub> Receptor Suggest a Conserved Hydrophobic Asparagine-Cage That Constrains the Activation of Class A G Protein-Coupled Receptors

Remko A. Bakker,<sup>1</sup> Aldo Jongejan, Kamonchanok Sansuk, Uli Hacksell, Henk Timmerman, Mark R. Brann, Dave M. Weiner,<sup>2</sup> Leonardo Pardo, and Rob Leurs

Leiden/Amsterdam Center for Drug Research, Department of Medicinal Chemistry, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands (R.A.B., A.J., K.S., H.T., and R.L.); ACADIA Pharmaceuticals Inc., San Diego, California (R.A.B., U.H., M.R.B., and D.M.W.); Department of Pharmacology, University of California at San Diego, San Diego, California (M.R.B.); Department of Neurosciences, University of California at San Diego, San Diego, California (D.M.W.); Department of Psychiatry, University of California at San Diego, San Diego, California (D.M.W.); and Laboratori de Medicina Computacional, Unitat de Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain (L.P.)

Received May 28, 2007; accepted October 16, 2007

## ABSTRACT

The aim of this study was to create and characterize constitutively active mutant (CAM) histamine H<sub>1</sub> receptors (H<sub>1</sub>R) using random mutagenesis methods to further investigate the activation process of the rhodopsin-like family of G protein-coupled receptors (GPCRs). This approach identified position 6.40 in TM 6 as a “hot spot” because mutation of Ile6.40<sup>420</sup> either to Glu, Gly, Ala, Arg, Lys, or Ser resulted in highly active CAM H<sub>1</sub>Rs, for which almost no histamine-induced receptor activation response could be detected. The highly conserved hydrophobic amino acid at position 6.40 defines, in a computational model of the H<sub>1</sub>R, the asparagine cage motif that restrains the

side chain of Asn7.49 of the NPxxY motif toward transmembrane domain (TM 6) in the inactive state of the receptor. Mutation of the asparagine cage into Ala or Gly, removing the interfering bulky constraints, increases the constitutive activity of the receptor. The fact that the Ile6.40<sup>420</sup>Arg/Lys/Glu mutant receptors are highly active CAM H<sub>1</sub>Rs leads us to suggest that a positively charged residue, presumably the highly conserved Arg3.50 from the DRY motif, interacts in a direct or an indirect (through other side chains or/and internal water molecules) manner with the acidic Asp2.50–Asn7.49 pair for receptor activation.

G protein-coupled receptors (GPCRs) play a crucial role in many physiological functions (Kristiansen, 2004) and are major drug targets (Hopkins and Groom, 2002). The notion of constitutive, agonist-independent signaling of GPCRs has fundamentally changed insights in receptor pharmacology. Receptor activity can be modulated by ligands that possess either negative (inverse agonists) or positive (agonists) intrinsic activity, whereas neutral antagonists lack intrinsic

activity and only compete for GPCR binding sites (reviewed in Seifert and Wieland, 2006). Constitutive receptor activity may also be induced by mutations. Such constitutively active mutant (CAM) GPCRs have been used to provide insight into the mechanism of receptor activation (Pardo et al., 2007; Smit et al., 2007).

It is now generally accepted that several highly conserved motifs, in the rhodopsin-like family of GPCRs, are key in the process of GPCR activation. First, a conserved hydrogen bond network linking Asp2.50 of the NLxxxD motif in transmembrane domain (TM) 2 with Trp6.48 of the CWxP motif in TM 6 maintains GPCRs in the inactive conformation (Li et al., 2004; Jongejan et al., 2005; Xu et al., 2005). This network of interactions constrains Trp6.48 in the inactive *gauche*<sup>+</sup> conformation, impeding its conformational transition toward the observed active *trans* conformation (Ruprecht et al., 2004).

This work was supported by the European Community (LSHB-CT-2003-503337), Ministerio de Educación y Ciencia (SAF2006-04966), and Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR2005-00390).

<sup>1</sup> Current affiliation: Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany.

<sup>2</sup> Current affiliation: Merck Serono, Boston, Massachusetts.

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>. doi:10.1124/mol.107.038547.

**ABBREVIATIONS:** GPCR, G protein-coupled receptor; CAM, constitutively active mutant; TM, transmembrane domain; H<sub>1</sub>R, H<sub>1</sub> receptor; R-SAT, receptor selection and amplification technology; NF-κB, nuclear factor κB; PCR, polymerase chain reaction; DMEM, Dulbecco's modified essential medium.

Second, Asn7.49 of the highly conserved NPxxY motif in TM 7 acts as an on/off switch by adopting alternative conformations in the inactive and active receptor states (Govaerts et al., 2001; Urizar et al., 2005). Asn7.49 is restrained toward TM 6 in the inactive *gauche*<sup>+</sup> conformation by molecular interactions that diverge among GPCR subfamilies (Urizar et al., 2005) or via a water molecule in rhodopsin (and possibly other receptors) (Okada et al., 2002). Upon receptor activation, Asn7.49 adopts the *trans* conformation to interact with Asp2.50 in TM 2 (Urizar et al., 2005). Third, the ionic lock between Arg3.50 of the highly conserved DRY motif in TM3 with its adjacent Asp/Glu3.49 residue (Scheer et al., 1996; Alewijnse et al., 2000; Ballesteros et al., 2001) and an additional Asp/Glu6.30 amino acid in TM 6 (Scheer et al., 1996; Alewijnse et al., 2000; Ballesteros et al., 2001). These ionic interactions are disrupted during the process of receptor activation, facilitating the movement of the cytoplasmic end of TM 6 and the conformational transition of Arg3.50 (Scheer et al., 1996; Alewijnse et al., 2000; Ballesteros et al., 2001).

The aim of this study was to create and characterize CAM histamine H<sub>1</sub> receptors (H<sub>1</sub>Rs) through random mutagenesis to further investigate the activation process of the rhodopsin-like family of GPCRs. Mutant receptors were initially screened using the receptor selection and amplification technology (R-SAT) functional assay, which has previously been successfully applied to identify, for instance, the G-protein-coupling domain of muscarinic receptors (Hill-Eubanks et al., 1996), as well as for the generation of CAM calcium-sensing (Jensen et al., 2000) and muscarinic (Spalding et al., 1997) receptors. Spalding et al. (1997) used the R-SAT procedure successfully to identify a face of TM6 of the muscarinic m5 receptor as a region to stabilize the inactive state and, therefore, as a hot spot for generating CAM GPCRs by random mutagenesis. Our initial functional R-SAT screen of randomly mutated H<sub>1</sub>Rs resulted in the identification of several highly constitutively active mutant H<sub>1</sub>Rs, which were further analyzed by assessing NF- $\kappa$ B activation in COS-7 cells as well as radioligand binding studies. In addition, rhodopsin-based molecular models of wild-type and mutant histamine H<sub>1</sub>Rs were built to explore the mechanisms responsible for constitutive activity. We provide the first examples of CAM H<sub>1</sub>Rs that harbor a mutation in the highly conserved hydrophobic amino acid residue 6.40 in TM 6. Furthermore, combining our observations with data from other GPCRs resulted in the identification of a putative hydrophobic cage for Asn7.49. This proposed Asn-cage is highly conserved in the family A GPCRs and seems to serve as an important constraint for GPCR activation.

## Materials and Methods

**Materials.** Cell culture media, penicillin, and streptomycin were obtained from Invitrogen (Merelbeke, Belgium). Cyto-SF3 was obtained from Kemp Laboratories (Frederick, MD) and [<sup>3</sup>H]-mepyramine (20 Ci/mmol) from PerkinElmer Life and Analytical Sciences (Zaventem, Belgium). Doxepin hydrochloride, mepyramine (pyrilamine maleate), and tripeleminamine hydrochloride were obtained from Sigma Aldrich (St. Louis, MO). ATP disodium salt, bovine serum albumin, chloroquine diphosphate, DEAE-dextran (chloride form), histamine dihydrochloride, and polyethylenimine were purchased from Sigma Chemical (St. Louis, MO). D-Luciferin was obtained from Duchefa Biochemie BV (Haarlem, The Netherlands), glycerol from Sigma-Aldrich Laborchemikalien (Seelze, Ger-

many), and Triton X-100 from Fluka (Buchs, Switzerland). pNF- $\kappa$ B-Luc was obtained from Stratagene (La Jolla, CA), pSI from Promega (Madison, WI), the TOPO 2.1 vector from Invitrogen (Carlsbad, CA), Superfect from QIAGEN (Dusseldorf, Germany), High-Fidelity Platinum *Taq*DNA Polymerase and High-Fidelity buffer from Invitrogen (Rockville, MD), and *Taq*DNA polymerase from Boehringer Mannheim (Mannheim, Germany). Gifts of mianserin hydrochloride (Organon NV, The Netherlands), pcDEF<sub>3</sub> (Dr. J. Langer, Robert Wood Johnson Medical School, Piscataway, NJ), are greatly acknowledged.

**Molecular Cloning.** The human H<sub>1</sub>R was cloned by PCR using the following oligodeoxynucleotide primers: 5' (5'-gct act aag tgg cca ctc atc acc caa gtc-3') and 3' (5'-caa cac aca ggc ctg cgg cgg cta ttt cct tg-3'). PCR conditions employed 100 ng (~125 pmol) of each primer, 250  $\mu$ M dNTPs, 80 ng of human genomic DNA, 2 mM MgSO<sub>4</sub>, 1 $\times$  High-Fidelity buffer, and 1.75 units of High-Fidelity Platinum *Taq*DNA Polymerase. PCR reactions conditions were: 94°C for 5 min; 30 cycles of 94°C for 30 s, 60°C for 35 s and 72°C for 95 s, followed by a final 10-min extension at 72°C. The resultant PCR product was subcloned into the TOPO 2.1 vector per the manufacturer's protocols and subsequently subcloned into the mammalian expression vector pSI for R-SAT-based functional studies.

**Mutagenesis of the Human H<sub>1</sub>R Gene and Isolation of CAM H<sub>1</sub>Rs.** Mutations were introduced into the human H<sub>1</sub>R gene by PCR. Plasmid pSIhH<sub>1</sub>R (Weiner et al., 2001) was used as template for all PCRs. The PCR primers were complementary to the H<sub>1</sub>R sequence, except for the codon corresponding to the desired amino acid residue in the H<sub>1</sub>R. Receptor genes containing mutations were constructed with a degenerate PCR primer that randomly introduced a combination of all four bases at the three positions of the codon that was to be mutated. CAM H<sub>1</sub>R genes were isolated by functional screening based on the ability of this mutant to activate growth of NIH 3T3 cells in the functional assay R-SAT in the absence of histamine, and the inhibition of agonist independent proliferative responses by 10  $\mu$ M mepyramine, an inverse H<sub>1</sub>R agonist (Bakker et al., 2000, 2001). For each residue that was mutated in the H<sub>1</sub>R, 25 potential mutant cDNAs were tested in this way (except for Ile<sup>433</sup>). Mutant H<sub>1</sub>Rs exhibiting the desired phenotype were subsequently sequenced to identify the amino acid substitution caused by the mutation that was introduced via PCR.


**Cell Culture and Transfection.** COS-7 African green monkey kidney cells were maintained at 37°C in a humidified 5% CO<sub>2</sub>/95% air atmosphere in Dulbecco's modified essential medium (DMEM) containing 2 mM L-glutamine, 50 IU/ml penicillin, 50  $\mu$ g/ml streptomycin, and 5% (v/v) fetal calf serum. COS-7 cells were transiently transfected using the DEAE-dextran method as described previously (Wieland et al., 1999; Bakker et al., 2000, 2001). NIH-3T3 cells were cultured in DMEM supplemented with 2 mM L-glutamine, 1% penicillin and streptomycin, and 10% bovine calf serum and maintained at 37°C in a humidified 5% CO<sub>2</sub>/95% air atmosphere. NIH-3T3 cells were transiently transfected using the Superfect transfection reagent following the manufacturer's protocols. The total amount of DNA transfected was maintained constant by addition of either pcDEF<sub>3</sub>, pSI, or pcDNA<sub>3</sub>.

**R-SAT Assays.** R-SAT assays were essentially performed as described previously (Weiner et al., 2001). In brief, on day 1, NIH-3T3 cells were plated into 96-well cell culture plates at a density of 7500 cells/well. On day 2, cells were transfected with 25 ng/well (mutant) H<sub>1</sub>R DNA, with 20 ng/well plasmid DNA encoding  $\beta$ -galactosidase. On day 3, the medium was replaced with DMEM supplemented with 1% penicillin and streptomycin, 2% Cyto-SF3, and varying drug concentrations. After 5 days of cell culture, medium was removed, and the cells were incubated in phosphate-buffered saline containing 3.5 mM *O*-nitrophenyl- $\beta$ -D-galactopyranoside, and 0.5% Nonidet P-40 detergent. The 96-well plates were incubated at room temperature for up to 8 h, and the resulting colorimetric reaction was measured by spectrophotometric analysis at 420 nm on an automated plate reader (Biotek Instruments Inc., Burlington, VT). Data were analyzed by a nonlinear, least-squares curve-fitting procedure


using Prism version 4 (GraphPad Software, Inc., San Diego, CA). All data shown are expressed as mean  $\pm$  S.E.M.

**Reporter-Gene Assays.** COS-7 cells transiently cotransfected with pNF $\kappa$ B-Luc (125  $\mu$ g/10<sup>7</sup> cells) and either pSIhH<sub>1</sub>R encoding the wild-

type human H<sub>1</sub>R or pSI plasmid DNA coding for the respective human H<sub>1</sub>R mutants were seeded in 96-well black plates (Costar; Corning Life Sciences, Acton, MA) in serum-free culture medium and incubated with drugs. After 48 h, cells were assayed for luminescence by aspiration of



**Fig. 1.** Functional R-SAT screen for the identification of CAM H<sub>1</sub>Rs. Selected amino acids in either the DRY motif (1), TM 5 (2), or TM 6 (3) of the human histamine H<sub>1</sub>R were mutated by PCR and subsequently screened for their constitutive activity. NIH-3T3 cells were transiently transfected with cDNAs encoding a potential mutant H<sub>1</sub>R and assayed for constitutive H<sub>1</sub>R activity. Data in the graph are plotted as the basal signal/observed signal in the presence of 10  $\mu$ M mepyramine, an inverse H<sub>1</sub>R agonist (Bakker et al., 2000, 2001). The dotted lines indicate the minimal and maximal effect obtained for the wild-type H<sub>1</sub>R under these assay conditions. Of the amino acids selected for mutagenesis, only a limited number of amino acid residues seem to be “hot spots” for the creation of CAM H<sub>1</sub>Rs: Ile6.40<sup>420</sup>, Ala6.43<sup>423</sup>, and Ile6.45<sup>425</sup>, whereas the random mutation of F6.54<sup>434</sup> and F6.55<sup>435</sup> may also yield CAM H<sub>1</sub>Rs. All these residues are located in TM 6.



**Fig. 2.** Effects of the expression of the various mutant H<sub>1</sub>Rs that are mutated at Ile6.40<sup>420</sup> in COS-7 cells on the basal activation of NF- $\kappa$ B. The basal activation of NF- $\kappa$ B by the wild-type H<sub>1</sub>R that is observed under the same experimental conditions is given as a comparison. Data shown is the average of five independent experiments, each performed in triplicate, and is expressed as the percentage of wild-type H<sub>1</sub>R-mediated basal NF- $\kappa$ B activation (WT on y-axis represents 100%).



TABLE 1

Pharmacological characterization of the mutant H<sub>1</sub>Rs obtained at the 16.40<sup>420</sup> position by NF-κB reporter gene assays

Assayed are the agonist histamine yielding a positive intrinsic activity (α) set to 1.0 and a variety of inverse H<sub>1</sub>R agonists. For each mutant H<sub>1</sub>R, the intrinsic activities of the inverse H<sub>1</sub>R agonists are related to the inverse H<sub>1</sub>R agonist yielding the greatest inhibition of mutant H<sub>1</sub>R-mediated basal NF-κB activation, which was set to -1.0 by definition. Data are presented as the mean of the indicated number of separate experiments (n), each of which was performed in triplicate. The S.E.M. values for the pEC<sub>50</sub> values are ≤0.1 unless indicated otherwise.

	H <sub>1</sub> R WT			H <sub>1</sub> R I6.40 <sup>420</sup> K			H <sub>1</sub> R I6.40 <sup>420</sup> F			H <sub>1</sub> R I6.40 <sup>420</sup> S			H <sub>1</sub> R I6.40 <sup>420</sup> A			H <sub>1</sub> R I6.40 <sup>420</sup> R			H <sub>1</sub> R I6.40 <sup>420</sup> G			H <sub>1</sub> R I6.40 <sup>420</sup> E		
	pEC <sub>50</sub>	α	n	pEC <sub>50</sub>	α	n	pEC <sub>50</sub>	α	n	pEC <sub>50</sub>	α	n	pEC <sub>50</sub>	α	n	pEC <sub>50</sub>	α	n	pEC <sub>50</sub>	α	n	pEC <sub>50</sub>	α	n
Histamine	6.8	1.0	89	6.6 <sup>a</sup>	1.0	2	6.6	1.0	8	N.E.	N.E.	4	6.7 <sup>b</sup>	1.0	5	6.1 <sup>c</sup>	1.0	7	7.1 <sup>b</sup>	1.0	5	7.4 <sup>a</sup>	1.0	4
Mepyramine	7.9	-0.9	89	6.2 <sup>a</sup>	-0.6	6	8.4 <sup>a</sup>	-0.6	4	6.5 <sup>b</sup>	4	7	6.5 <sup>b</sup>	-0.6	7	6.5 <sup>b</sup>	-0.6	5	6.7 <sup>a</sup>	-0.7	3	5.3 <sup>c</sup>	-0.8	3
Cyproheptadine	8.5	-0.9	12	7.1	-1.0	6	8.6 <sup>a</sup>	-0.9	4	8.1 <sup>a</sup>	-1.0	7	7.4	-1.0	7	7.0	-1.0	7	7.5	-1.0	7	7.6	-1.0	7
Ketotifen	9.2	-0.9	10	7.8 <sup>a</sup>	-0.8	5	9.4	-0.8	3	8.3	-0.9	3	7.8 <sup>a</sup>	-0.9	6	7.7 <sup>a</sup>	-0.9	3	8.2 <sup>a</sup>	-0.9	3	8.1	-0.9	3
Doxepin	9.3	-0.9	12	7.2 <sup>a</sup>	-0.7	3	8.7	-0.9	3	7.6 <sup>a</sup>	-0.9	3	7.2 <sup>d</sup>	-0.8	3	6.9 <sup>a</sup>	-0.7	3	7.5	-0.9	3	7.3 <sup>b</sup>	-0.8	3
Mianserin	8.8	-0.9	9	6.9	-0.9	5	8.3 <sup>a</sup>	-0.9	3	7.8	-0.9	5	7.5 <sup>a</sup>	-1.0	5	6.9	-0.9	5	7.7	-1.0	5	7.6 <sup>a</sup>	-1.0	5
Triptolennamine	7.4	-0.8	11	5.7 <sup>a</sup>	-0.5	7	7.2 <sup>a</sup>	-0.8	3	5.9	-0.8	4	5.3 <sup>a</sup>	-0.7	7	5.4	-0.8	3	5.8 <sup>a</sup>	-0.8	4	N.D.	N.D.	
d-Chlorpheniramine	7.8	-0.9	7	5.5 <sup>b</sup>	-0.7	5	8.0 <sup>a</sup>	-0.6	3	6.0 <sup>a</sup>	-0.7	3	6.1 <sup>a</sup>	-0.7	3	6.0 <sup>a</sup>	-0.7	3	7.6 <sup>a</sup>	-0.7	3	N.D.	N.D.	
Mirtazapine	9.2 <sup>a</sup>	-0.9	3	7.6 <sup>c</sup>	-0.6	3	9.1	-0.7	3	8.2 <sup>c</sup>	-0.8	3	8.3 <sup>b</sup>	-0.7	3	7.8	-0.6	3	6.3 <sup>a</sup>	-0.6	3	N.D.	N.D.	
Tripolidine	8.3	-0.7	11	6.1	-0.8	3	8.6 <sup>a</sup>	-0.6	3	6.7 <sup>a</sup>	-0.9	3	6.8 <sup>b</sup>	-0.6	3	6.4	-0.8	3	6.7	-0.8	3	N.D.	N.D.	
Levocabastine	8.0	-1.0	14	6.3	-0.8	3	7.4 <sup>a</sup>	-0.9	4	6.8 <sup>b</sup>	-0.9	3	6.4 <sup>b</sup>	-0.8	3	6.3	-0.8	3	6.5	-0.9	3	6.3	-1.0	3
Astemizole	8.3 <sup>a</sup>	-1.0	7	7.3	-1.0	3	7.9 <sup>b</sup>	-1.0	3	7.5	-1.0	3	7.5 <sup>a</sup>	-0.9	4	7.5	-1.0	3	7.5	-1.0	3	8.1	-0.5	3
Loratadine <sup>f</sup>	6.4 <sup>a</sup>	-1.0	10	5.4	-0.9	5	5.4	-1.3	3	5.4	-1.0	3	5.4	-0.9	6	5.3	-1.1	3	5.2	-1.0	3	5.2	-1.2	3

N.E., could not be determined; N.D., not determined.

<sup>a</sup> S.E.M. ≤ 0.2.

<sup>b</sup> S.E.M. ≤ 0.3.

<sup>c</sup> S.E.M. ≤ 0.4.

<sup>d</sup> S.E.M. ≤ 0.5.

<sup>e</sup> S.E.M. ≤ 0.6.

<sup>f</sup> Loratadine was not taken as a reference full inverse agonist with an intrinsic activity (α) of -1 because of its previously reported inhibition of non-H<sub>1</sub>R mediated NF-κB activation in this assay (Bakker et al., 2001).

the medium and the addition of 25 μl/well luciferase assay reagent [0.83 mM ATP, 0.83 mM D-luciferin, 18.7 mM MgCl<sub>2</sub>, 0.78 μM Na<sub>2</sub>H<sub>2</sub>P<sub>2</sub>O<sub>7</sub>, 38.9 mM Tris, pH 7.8, 0.39% (v/v) glycerol, 0.03% (v/v) Triton X-100, and 2.6 μM dithiothreitol]. After 30 min, luminescence was measured for 3 s/well in a Victor<sup>2</sup> microplate reader (PerkinElmer Life and Analytical Sciences). All data shown are expressed as mean ± S.E.M.

**H<sub>1</sub>R Binding Studies.** Cells used for radioligand binding-studies were harvested 48 h after transfection and homogenized in ice-cold H<sub>1</sub>R binding buffer (50 mM Na<sub>2</sub>/K<sup>+</sup>-phosphate buffer, pH 7.4). The cell homogenates were incubated for 30 min at 25°C in a total volume of 200 μl of H<sub>1</sub>R binding buffer with ~1 nM [<sup>3</sup>H]mepyramine. The nonspecific binding was determined in the presence of 1 μM ketotifen. The incubations were stopped by rapid dilution with 3 ml of ice-cold H<sub>1</sub>R binding buffer. The bound radioactivity was separated by filtration through Whatman GF/C filters (Whatman, Clifton, NJ) that had been treated with 0.3% polyethylenimine. Filters were washed twice with 3 ml of buffer, and radioactivity retained on the filters was measured by liquid scintillation counting.

**Molecular Models of Wild-Type and Mutant H<sub>1</sub>Rs.** The previously reported three-dimensional model of the H<sub>1</sub>R was employed (Jongejan et al., 2005). Molecular models for the mutant H<sub>1</sub>Rs were obtained as described in our previous report (Jongejan et al., 2005). In the I6.40<sup>420</sup>K, I6.40<sup>420</sup>R, and I6.40<sup>420</sup>S mutant H<sub>1</sub>Rs, the side chain of Asn7.49 is modeled in the proposed active *trans* conformation and is interacting with Asp2.50<sup>73</sup> (Urizar et al., 2005). The accessible surface of the O<sub>6</sub> atom of Asn7.49<sup>464</sup>, in the inactive conformation, was obtained with the NACCESS program (Hubbard and Thornton, University College London).

**Analytical Methods.** All data shown are expressed as mean ± S.E.M. Protein concentrations were determined according to the method of Bradford (1976), using BSA as a standard. Data from radioligand binding assays and functional assays data were evaluated by a nonlinear, least-squares curve-fitting procedure using GraphPad Prism version 4.


## Results

**Generation and Identification of CAM H<sub>1</sub>Rs.** A variety of amino acids in the human histamine H<sub>1</sub>R were selected for mutagenesis (Fig. 1). These include amino acids present in the highly conserved DRY motif in TM 3, the top of TM 5, and of TM 6. These regions of the hH<sub>1</sub>R were selected based on the well documented role of both the DRY motif and TM 6 in activation of class A GPCRs (reviewed in Gether et al., 2002; Flanagan, 2005). In contrast, the top of TM 5 was chosen for its role in interaction with antihistamines (Wieland et al., 1999), which are currently known as inverse H<sub>1</sub>R agonists (Bakker et al., 2000, 2001), and was therefore postulated to be involved in H<sub>1</sub>R inactivation. The random saturation mutagenesis was performed via PCR with degenerate primers as described under *Materials and Methods*. A fair number of mutant receptor cDNAs were generated by this method. However, the wild-type receptor was clearly preferably generated in this approach, in that it was largely present in each pool of cDNAs that was generated. Our approach certainly did not result in the generation of all possible mutant H<sub>1</sub>Rs at the selected amino acids that were included in the mutagenesis approach. Yet the PCR with degenerate primers approach resulted in a number of arbitrary H<sub>1</sub>R mutants that were evaluated for their signaling properties in our quest for CAM H<sub>1</sub>Rs.

A variety of assays have been used to demonstrate constitutive H<sub>1</sub>R activity since our initial demonstration of this phenomenon for the H<sub>1</sub>R (Bakker et al., 2000). These assays include the measurements of inositol phosphates (Bakker et

al., 2000), cell shape (Yu et al., 2006), and the activities of a variety of reporter genes (Bakker et al., 2001; Weiner et al., 2001; Smit et al., 2002; Wu et al., 2004). Because we aimed at the generation and characterization of a large number of mutant receptors, we selected R-SAT functional assays for

the initial characterization because the R-SAT assay is extremely robust, allows high throughput, and yields a similar  $H_1R$  pharmacological profile for a wide variety of inverse  $H_1R$  agonists compared with the more standard NF- $\kappa$ B reporter-gene assay (see Bakker et al., 2007).



**Fig. 3.** Effects of histaminergic ligands on mutant  $H_1R$ -mediated activation of NF- $\kappa$ B. Modulation of NF- $\kappa$ B activation by the various isolated mutant  $H_1R$ s that are mutated at Ile6.40<sup>420</sup> by the  $H_1R$  agonist histamine (●) and the inhibition of constitutive NF- $\kappa$ B activation by the inverse  $H_1R$  agonist cyproheptadine (○). Representative concentration response curves are shown. The maximum effect observed for histamine was set to 100% stimulation.

The initial functional screen using mutated H<sub>1</sub>Rs, consisting of the evaluation of H<sub>1</sub>R signaling under both basal conditions and after incubation with 10  $\mu$ M mepyramine, an inverse H<sub>1</sub>R agonist, identified several residues in the H<sub>1</sub>R that upon mutation could yield CAM H<sub>1</sub>Rs, including some receptors with mutations in the DRY motif. However, three residues were identified in TM 6 (Ile6.40<sup>420</sup>, Ala6.43<sup>423</sup>, or Ile6.45<sup>425</sup>) that are very prone to yield highly activated CAM H<sub>1</sub>Rs upon mutation (Fig. 1). From our experimental approach, especially mutant H<sub>1</sub>Rs with a mutation at position 6.40<sup>420</sup> jump out and were therefore analyzed in more detail. All potential mutant H<sub>1</sub>Rs harboring a mutation at this position were subsequently sequenced and characterized by NF- $\kappa$ B reporter gene assays.

**Functional Evaluation of CAM H<sub>1</sub>Rs.** Of the evaluated mutants, the H<sub>1</sub>Rs mutated at position 6.40<sup>420</sup> exhibited the

largest degree of constitutive signaling (Figs. 1 and 2). Mutation of Ile6.40<sup>420</sup> to either Glu, Gly, Ala, Arg, Lys, or Ser results in highly active CAM H<sub>1</sub>Rs for which almost no additional histamine-induced receptor activation can be detected. Thus, these receptors appear to be fully activated because of their respective mutations (Fig. 2). Among the mutations we have analyzed, the I6.40<sup>420</sup>F mutation constitutes a unique substitution at this position, exhibiting a level of constitutive activity comparable with that of the wild-type H<sub>1</sub>R (Fig. 2 and Table 1).

Histamine and a variety of inverse H<sub>1</sub>R agonists were subsequently assayed for their potency and intrinsic activity ( $\alpha$ ) for the mutant H<sub>1</sub>R6.40<sup>420</sup> receptors (Table 1). The ability of histamine to activate the mutant H<sub>1</sub>R6.40<sup>420</sup> receptors greatly varied depending on the mutant. Whereas the H<sub>1</sub>R I6.40<sup>420</sup>F mutant receptor was activated by histamine simi-




Fig. 4. Correlation graphs of the potencies of various histaminergic ligands for the wild-type H<sub>1</sub>R versus the Ile6.40<sup>420</sup> mutant H<sub>1</sub>Rs. The potencies of various inverse H<sub>1</sub>R agonists (●) to mediate the inhibition of constitutive wild-type or mutant H<sub>1</sub>R-induced activation of NF- $\kappa$ B are plotted, as well as the potency of histamine to induce wild-type and mutant H<sub>1</sub>R-mediated NF- $\kappa$ B activation (○); see also Table 1. The dotted lines represent the 95% confidence bands of the best-fit line; the H<sub>1</sub>R agonist histamine was not included in the fitting of the inverse H<sub>1</sub>R agonist data.



larly to the wild-type receptor, for other mutant receptors, notably the H<sub>1</sub>R I6.40<sup>420</sup>R, H<sub>1</sub>R I6.40<sup>420</sup>E, H<sub>1</sub>R I6.40<sup>420</sup>K, and H<sub>1</sub>R I6.40<sup>420</sup>S mutant receptors, hardly any histamine-induced activation could be detected (see also Fig. 3). The pharmacological profiles of the evaluated inverse H<sub>1</sub>R agonists also varied depending on the mutation in the H<sub>1</sub>R receptor. Whereas  $\alpha$  for most tested inverse H<sub>1</sub>R agonists remained constant for the mutant H<sub>1</sub>R6.40<sup>420</sup> receptors, the  $\alpha$  values for mepyramine, *d*-chlorpheniramine, and mirtazapine exhibited a mutant H<sub>1</sub>R6.40<sup>420</sup> receptor-dependent variation with the general tendency of becoming weaker partial inverse H<sub>1</sub>R agonists for the mutant H<sub>1</sub>R6.40<sup>420</sup> receptors. The potencies of the inverse H<sub>1</sub>R agonists obtained for the mutant H<sub>1</sub>R6.40<sup>420</sup> receptors, on the other hand, indicate that the potencies of cyproheptadine, astemizole, and loratadine are reduced to a lesser extent than that observed for the other tested inverse H<sub>1</sub>R agonists, whereas in comparison, those of doxepin and *d*-chlorpheniramine are reduced to a greater extent (Table 1). Figure 3 illustrates the differences observed in the pharmacological profiles of histamine and cyproheptadine for the various mutant H<sub>1</sub>R6.40<sup>420</sup> receptors as well as the differences observed in the basal activity of the mutant receptors.

As shown in Fig. 4, a linear correlation was found between the pIC<sub>50</sub> values of the inverse H<sub>1</sub>R agonists obtained for the wild-type H<sub>1</sub>R and for the H<sub>1</sub>Rs mutated at position 6.40, and the slope of the correlation seemed not to be influenced by the mutations. The intercept of the correlation, however, was clearly rightward shifted for the CAM H<sub>1</sub>Rs compared with the H<sub>1</sub>R6.40<sup>420</sup>F receptor, which exhibited a constitutive activity comparable with that of the wild-type H<sub>1</sub>R, suggesting that higher concentrations of inverse H<sub>1</sub>R agonist are required to silence the constitutive activity of the identified highly active CAM H<sub>1</sub>Rs.

#### Radioligand Binding Studies of Ile6.40<sup>420</sup> Mutants.

We evaluated the binding characteristics of [<sup>3</sup>H]mepyramine to wild-type and mutant H<sub>1</sub>Rs upon expression in COS-7 cells. The lower potency of mepyramine observed for the mutant receptors in the functional studies suggested that saturation binding assays were not feasible for characterization of all mutant H<sub>1</sub>R6.40<sup>420</sup> receptors because high amounts of radioligand would be required. We therefore performed homologous displacement studies to determine the pK<sub>b</sub> value of [<sup>3</sup>H]mepyramine for the mutant H<sub>1</sub>R6.40<sup>420</sup> receptors as well as to estimate their respective expression levels (*B*<sub>max</sub> values) upon heterologous expression (Table 2).

Analysis of the binding data indicated that the expression levels of the mutant H<sub>1</sub>R6.40<sup>420</sup> receptors was considerably lower than that of the wild-type H<sub>1</sub>R. In particular, the mutant H<sub>1</sub>RI6.40<sup>420</sup>E and H<sub>1</sub>RI6.40<sup>420</sup>K receptors, and to a lesser extent H<sub>1</sub>RI6.40<sup>420</sup>S and H<sub>1</sub>RI6.40<sup>420</sup>A, had expression levels that were approximately 10 and 25% of the expression level achieved for the wild-type H<sub>1</sub>R, respectively. The mutant H<sub>1</sub>RI6.40<sup>420</sup>F, H<sub>1</sub>RI6.40<sup>420</sup>R, and H<sub>1</sub>RI6.40<sup>420</sup>G receptors reached expression levels of approximately 40 to 50% of that observed for the wild-type H<sub>1</sub>R. Except for the mutant H<sub>1</sub>R6.40<sup>420</sup>S and H<sub>1</sub>R6.40<sup>420</sup>G receptors, where [<sup>3</sup>H]mepyramine bound approximately 3-fold less potently than to the wild-type H<sub>1</sub>R, the pK<sub>b</sub> values obtained for [<sup>3</sup>H]mepyramine binding to the mutant H<sub>1</sub>R6.40<sup>420</sup> receptors were rather similar to the values for the wild-type H<sub>1</sub>R. We subsequently determined the affinities of histamine for the

mutant H<sub>1</sub>R6.40<sup>420</sup> receptors. Whereas both H<sub>1</sub>R6.40<sup>420</sup>F and H<sub>1</sub>R6.40<sup>420</sup>S receptors exhibited affinities for histamine equal to the affinity of histamine for the wild-type H<sub>1</sub>R, the other mutant H<sub>1</sub>R6.40<sup>420</sup> receptors exhibited substantially higher affinity for histamine than did the wild-type H<sub>1</sub>R (Table 2). These data indicate that for some, but not all (H<sub>1</sub>R6.40<sup>420</sup>S), CAM H<sub>1</sub>Rs, the affinity toward the endogenous agonist was increased.

#### Molecular Modeling of Ile6.40<sup>420</sup> Mutant Receptors.

Ile6.40<sup>420</sup> was located between Arg3.50<sup>125</sup> of the DRY motif in TM 3 and Asn7.49<sup>464</sup> of the NPxxY motif in TM 7 (Fig. 5). Consequently, the observed effects of the different Ile6.40<sup>420</sup> mutations on the constitutive H<sub>1</sub>R activity probably can be explained by modification of any of these key motifs. Insertion of a negatively charged side chain at this locus in the I6.40<sup>420</sup>E mutation facilitates the interaction with Arg3.50<sup>125</sup> (Fig. 6A). This is in agreement with previous suggestions that Arg3.50<sup>125</sup> performs a conformational change, during the process of receptor activation, from being engaged in the ionic lock with the contiguous Asp3.49<sup>124</sup> and Glu6.30<sup>410</sup> in the inactive state (Ballesteros et al., 2001) to point toward the protein core (Ballesteros et al., 1998). Based on our modeling and mutational data, we propose that Arg3.50<sup>125</sup> elicits the conformational change from the inactive  $\chi_1$ :*trans*,  $\chi_2$ :*gauche*<sup>-</sup>,  $\chi_3$ :*gauche*<sup>+</sup>,  $\chi_4$ :*gauche*<sup>-</sup> (Fig. 5A) to the active  $\chi_1$ :*gauche*<sup>+</sup>,  $\chi_2$ :*trans*,  $\chi_3$ :*trans*,  $\chi_4$ :*trans* conformations (Figs. 5B and 6A). In contrast, addition of the positively charged side chain of either Arg or Lys in the I6.40<sup>420</sup>R or I6.40<sup>420</sup>K mutant receptors modified Asn7.49<sup>464</sup> of the NPxxY motif. We have proposed recently that Asn7.49<sup>464</sup> changes its conformation from pointing toward TM 6 in the inactive *gauche*<sup>+</sup> conformation, to interact with Asp2.50<sup>73</sup> in the active *trans* conformation (Govaerts et al., 2001; Urizar et al., 2005). The formation of the Asp2.50<sup>73</sup>-Asn7.49<sup>464</sup> pair conveys acidic properties to the Asn7.49<sup>464</sup> side chain (Urizar et al., 2005). Thus, either Arg or Lys in the I6.40<sup>420</sup>R or I6.40<sup>420</sup>K mutant receptors, respectively, interacted with the acidic O<sub>δ</sub> atom of Asn7.49<sup>464</sup> (Fig. 6, B and C). Likewise, Ser6.40<sup>420</sup> in the I6.40<sup>420</sup>S mutant receptor stabilized this active conformation of Asn7.49<sup>464</sup> by forming a hydrogen bond interaction between both side chains (data not shown). During the preparation of this article, Proneth et al. (2006) suggested the potential involvement of a rearrangement of hydrogen bonding networks between 6.40 in TM6 and the

TABLE 2

Expression levels of the various Ile6.40<sup>420</sup> mutant H<sub>1</sub>Rs upon transfection of COS-7 cells (*B*<sub>max</sub> values), their affinity for mepyramine as determined by homologous [<sup>3</sup>H]mepyramine displacement studies (pK<sub>b</sub> values), and their subsequently determined affinities (pK<sub>i</sub> values) for histamine

Data are presented as means  $\pm$  S.E.M. of at least three separate experiments, each performed in triplicate.

Receptor	<i>B</i> <sub>max</sub> pmol/mg protein	pK <sub>b</sub> [ <sup>3</sup> H]Mepyramine	pK <sub>i</sub> Histamine
H <sub>1</sub> R WT	44 $\pm$ 11	8.0 $\pm$ 0.1	6.0 $\pm$ 0.4
H <sub>1</sub> R I6.40 <sup>420</sup> K	5 $\pm$ 1	8.2 $\pm$ 0.1	7.4 $\pm$ 0.1
H <sub>1</sub> R I6.40 <sup>420</sup> F	23 $\pm$ 1	8.1 $\pm$ 0.1	5.9 $\pm$ 0.3
H <sub>1</sub> R I6.40 <sup>420</sup> S	10 $\pm$ 2	7.5 $\pm$ 0.1	6.0 $\pm$ 0.1
H <sub>1</sub> R I6.40 <sup>420</sup> A	11 $\pm$ 1	8.2 $\pm$ 0.1	6.9 $\pm$ 0.2
H <sub>1</sub> R I6.40 <sup>420</sup> R	18 $\pm$ 1	7.7 $\pm$ 0.1	7.4 $\pm$ 0.1
H <sub>1</sub> R I6.40 <sup>420</sup> G	18 $\pm$ 5	7.6 $\pm$ 0.1	7.2 $\pm$ 0.1
H <sub>1</sub> R I6.40 <sup>420</sup> E	4 $\pm$ 1	7.9 $\pm$ 0.1	6.7 $\pm$ 0.1

DRY and NPxxY motifs, as the explanation for the observed constitutive activity of the hMC4R L6.40<sup>250</sup>Q mutant (Proneth et al., 2006). Their findings corroborate and strengthen our findings on the proposed role of residue 6.40 in GPCR activation.


It is noteworthy that mutation of Ile6.40<sup>420</sup> to either Ala or Gly also caused a significant increase in the constitutive activity of the resultant mutant H<sub>1</sub>Rs, which is comparable with the magnitude of constitutive activity of the mutant H<sub>1</sub>R I6.40<sup>420</sup>R receptor. Thus, the side chain of Ile6.40<sup>420</sup> played an important role in maintaining an inactive state of

the receptor. We hypothesize that the bulky and  $\beta$ -branched Ile6.40<sup>420</sup> buried the O <sub>$\delta$</sub>  atom of Asn7.49<sup>464</sup> from the intracellular counterpart (i.e., a positive charge, see *Discussion*). The accessible surface (see *Materials and Methods*) of the O <sub>$\delta$</sub>  atom, in the inactive conformation of Asn7.49<sup>464</sup> (Fig. 5A), was 0.5 Å<sup>2</sup> in the wild-type receptor and increased to 6.5 or 8.5 Å<sup>2</sup> in the mutation of Ile6.40<sup>420</sup> to Ala or Gly, respectively. Thus, removal of the Ile6.40 side-chain through mutation into Ala or Gly rendered the O <sub>$\delta$</sub>  atom accessible, hence facilitating the conformational transition of Asn7.49<sup>464</sup> toward Asp2.50<sup>73</sup>.


## Discussion

Activation of GPCRs is thought to involve disruption of intramolecular interactions that stabilize their inactive conformations. Such disruptions are induced by agonists but may also be induced upon mutation of the receptor. Disruption of these stabilizing interactions has a large energetic cost that must be compensated by the formation of new stabilizing interactions in the resulting active state of the receptor. In the present work, based on our pharmacological data for CAM H<sub>1</sub>Rs that were obtained through a random mutagenesis approach, complemented with a molecular modeling approach, we propose stabilizing interactions acting at both the inactive and the active states of the H<sub>1</sub>R.

On the basis of both our observations and previous work by others, we suggest Asp2.50 is involved in maintaining Trp6.48 pointing toward TM 7 in the inactive receptor state (Fig. 5A) through a conserved hydrogen bond network (Pardo et al., 2007; Smit et al., 2007). This network of interactions impedes the reported conformational transition of Trp6.48 from pointing toward TM7, in inactive rhodopsin, to pointing toward TM5, in metarhodopsin I (Ruprecht et al., 2004). Binding of agonists to the extracellular domain of the receptor modifies the conformation of Trp6.48 toward TM5 through a specific hydrogen bond interaction (López-Rodríguez et al., 2005). The rotamer toggle switch of Trp6.48 occurs in a concerted manner with the side chain at position 3.36 (Fig. 5B) (Jongejan et al., 2005; Urizar et al., 2005). These conformational transitions of Ser3.36 and Trp6.48 have two effects in the structure of the helical bundle. First, they disrupt the conserved hydrogen bond network between



**Fig. 5.** A, computational model of the histamine H<sub>1</sub>R in the inactive state showing the local environment of Ile6.40<sup>420</sup>. The hydrogen bond network linking Asp2.50<sup>73</sup> and Trp6.48<sup>428</sup>, the water-mediated interhelical interaction between Asn7.49<sup>464</sup> and the backbone carbonyl at position 6.40; and the ionic interaction between Arg3.50<sup>125</sup> and Asp3.49<sup>124</sup> and Glu6.30<sup>410</sup> are shown. B, schematic representation of the conformational changes of the Ser3.36<sup>111</sup>/Trp6.48<sup>428</sup> concerted rotamer toggle switch; the conformational transition of Asn7.49<sup>464</sup> toward Asp2.50<sup>73</sup>; and the conformational change of Arg3.50<sup>125</sup> toward the protein core, during the process of histamine H<sub>1</sub>R activation. This modeling exercise aims only at exploring these localized rotamer changes, which correspond to early stages of the activation process when side chain relocations have not yet been translated into major conformational changes of TM segments (Ruprecht et al., 2004), probably through a structural reorganization of the highly conserved proline-induced distortions. Structural water molecules 1a and 1c that mediate interhelical interactions are also shown (Pardo et al., 2007; Smit et al., 2007). Only polar hydrogens are depicted for clarity. The color code for the  $\alpha$ -carbon ribbons are goldenrod (TM 2), dark red (TM 3), orange (TM 6), and blue (TM 7).



**Fig. 6.** Computational model of I6.40<sup>420</sup>E (A), I6.40<sup>420</sup>R (B), and I6.40<sup>420</sup>K mutant receptors (C). A, Glu6.40<sup>420</sup> in the I6.40<sup>420</sup>E mutant receptor triggers the conformational change of Arg3.50<sup>125</sup> from being engaged in the ionic lock with the contiguous Asp3.49<sup>124</sup> and Glu6.30<sup>410</sup> in the inactive state to point toward the protein core. It is not possible to determine the conformation of Asn7.49<sup>464</sup> in this mutant receptor; thus, it has been modeled arbitrarily as in the inactive state. B and C, Arg6.40<sup>420</sup> and Lys6.40<sup>420</sup> in the I6.40<sup>420</sup>R or I6.40<sup>420</sup>K mutant receptors trigger the conformational change of Asn7.49<sup>464</sup> toward Asp2.50<sup>73</sup>. It is not possible to determine the conformation of Arg3.50<sup>125</sup> in these mutant receptors; thus, it has been modeled arbitrarily engaged in the ionic lock as in the inactive state. Only polar hydrogens are depicted for clarity. The color code for the  $\alpha$ -carbon ribbons are goldenrod (TM 2), dark red (TM 3), orange (TM 6), and blue (TM 7).



Trp6.48 and Asp2.50, triggering the conformational transition of Asn7.49 toward Asp2.50 (Fig. 5B) (Jongejan et al., 2005; Urizar et al., 2005). Second, they decrease the proline-kink of TM 6, leading to movement of the cytoplasmic end of TM 6 away from TM 3, disrupting the ionic interaction between Arg3.50 with the nearby negatively charged side chains at positions 3.49 and 6.30 (Shi et al., 2002).

The mutant H<sub>1</sub>Rs that we generated in this study have largely been characterized upon transient expression in COS-7 cells. We observed differences in expression levels between the wild-type and mutant receptors that could be due, at least in part, to an increased instability of CAM receptors, like our previous findings for CAM H<sub>2</sub>Rs having mutations in the DRY motif (Alewijnse et al., 2000). However, the instability of the receptor protein or its expression does not seem to be solely correlated with the level of its constitutive activity. The I6.40<sup>420</sup>F mutant showed a level of constitutive activity comparable with the wild-type receptor but had a reduced expression level. Therefore, as-yet-unidentified mechanisms contribute to the overall lower expression levels of these mutant receptors.

In this article, we have shown that the physicochemical properties of the amino acid side chain at position 6.40 in TM 6 were key in the process of receptor activation because it is located midway between the NPxxY motif and the ionic lock (Fig. 5). Statistical analysis shows that GPCRs do not contain either positive (Arg, Lys) or negative (Asp, Glu) side chains at this locus (Mirzadegan et al., 2003). I6.40R or I6.40K mutant receptors are highly active CAM H<sub>1</sub>Rs with almost no additional histamine-induced activation (Fig. 3). Thus, Arg6.40 or Lys6.40 was not observed in the rhodopsin family of GPCRs because a positively charged residue at this position would induce constitutive receptor activation by triggering the conformational change of Asn7.49 toward Asp2.50 (Fig. 6, B and C). Remarkably, insertion of a negatively charged residue (the I6.40E mutant receptor) at this 6.40 position also induces histamine H<sub>1</sub>R constitutive activity (Fig. 3). In contrast to I6.40R or I6.40K, the I6.40E mutant receptor disrupts the ionic lock between the cytoplasmic ends of TM 3 and 6 by triggering the conformational change of Arg3.50 toward the protein core (Fig. 6A). It is noteworthy that Arg6.40 or Lys6.40 in the I6.40R or I6.40K mutant receptors create an intracellular positive field, which is similar to the positive field created by Arg3.50 in the I6.40E mutation because of their similar positions (Fig. 6, compare A with B and C). Thus, the fact that insertion of either a negatively or positively charged side chain at the 6.40 position enhances constitutive H<sub>1</sub>R activity suggests that the creation of this positive electrostatics between TMs 3, 6, and 7 is an important determinant for receptor activation. These findings let us to propose that the highly conserved Arg3.50 of the (D/E)RY motif at the bottom of TM 3 performed a conformational change from being engaged in the ionic lock with the contiguous Asp3.49 and Glu6.30 in the inactive state (Fig. 5A) to interact with the Asp2.50–Asn7.49 pair in the active state of wild-type H<sub>1</sub>R (Fig. 5B). Because the distance between these two motifs, as observed in the crystal structure of rhodopsin, is large, we suggest either a direct interaction, if rigid-body movements of the TM helices occur, or an indirect interaction through other side chains or/and internal water molecules. This proposal is in agreement with previous findings: 1) addition of the N7.49A mutation to the highly

constitutively active E3.49A or E3.49Q mutant receptors, which releases Arg3.50 from the ionic lock, dramatically lowered the constitutive activity of the double mutants to levels of wild type for the thyrotropin receptor (Claeysen et al., 2002). Thus, the release of the Arg3.50 side chain by mutation of Glu3.49 was stable only in the presence of Asn7.49. 2) Likewise, the E3.49Q mutation in rhodopsin favored the formation of metharhopsin II, whereas the double E3.49Q/N7.49A mutation decreases the relative activation rate (Fritze et al., 2003). These data led the authors to propose a clear interplay between Asn7.49 of the NPxxY motif and the (D/E)RY motif. 3) Finally, the D2.50N point mutation in the M<sub>3</sub> muscarinic receptor abolishes agonist-induced receptor/G-protein coupling in yeast, whereas the D2.50N/R3.50M and D2.50N/R3.50W double mutant receptors showed  $E_{\max}$  values similar to the wild-type receptor (Li et al., 2005). The authors proposed a conformational link between Asp2.50 and Arg3.50, which is critical for receptor activation.

It is noteworthy that the 6.40 position seems to be a highly conserved hydrophobic residue in the rhodopsin-like family of GPCRs (Leu, 14%; Val, 42%; Ile, 28%; Met, 5%) (Mirzadegan et al., 2003). Removal of this hydrophobic and bulky side chain (mutation to Ala or Gly) induced constitutive activity comparable in magnitude to addition of a positively (mutation to Arg or Lys) or a negatively (mutation to Glu) charged side chain at this locus (Figs. 1 and 2). The mechanistic role of Ile6.40 probably is to restrain Asn7.49 in the inactive *gauche*<sup>+</sup> conformation. Thus, as with the arginine cage (Ballasteros et al., 1998), we would like to propose that Asn7.49 is also located in a cage that restrains its conformation toward TM 6 in the inactive state. The asparagine cage is formed, in addition to this hydrophobic side chain at position 6.40, by the hydrophobic Leu2.46 of the NLxxxD motif in TM 2 of the H<sub>1</sub>R (Fig. 5). Removal (mutation to Ala or Gly) of the bulky and  $\beta$ - or  $\gamma$ -branched hydrophobic side chain at positions 2.46 in rhodopsin (Madabushi et al., 2004) or the thyrotropin receptor (Urizar et al., 2005); or 6.40 in rhodopsin (Han et al., 1996), the serotonin 5HT<sub>2A</sub> receptor (Shapiro et al., 2002), and the H<sub>1</sub>R (Figs. 1 and 2) induces constitutive activity. These considerations make us propose that the suggested constraining action of the Asn-cage in the H<sub>1</sub>R might be more widespread in the family of class A GPCRs.

The crystal structure of the  $\beta_2$ -adrenergic receptor, determined at 2.4-Å resolution, has been published (Cherezov et al., 2007) while this article was in production. A significant difference between this structure and rhodopsin resides in a partial disruption of the ionic lock between TMs 3 and 6. Consequently, the distance between the C $\alpha$  atoms of Asn7.49 and the hydrophobic amino acid at position 6.40 is shorter in the  $\beta_2$ -adrenergic receptor (6.2 Å) than in rhodopsin (6.8 Å). Thus, this new structure further supports that Ile6.40, forming the Asn-cage, has an active role in restraining Asn7.49 in the inactive conformation.

#### Acknowledgments

We thank Anne Watts, Herman Hofman, and Anne Marie Trip for expert assistance.

#### References

- Alewijnse AE, Timmerman H, Jacobs EH, Smit MJ, Roovers E, Cotecchia S, and Leurs R (2000) The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H<sub>2</sub> receptor. *Mol Pharmacol* 57:890–898.

- Bakker RA, Nicholas MW, Smith TT, Burstein ES, Hacksell U, Timmerman H, Leurs R, Brann MR, and Weiner DM (2007) In vitro pharmacology of clinically used central nervous system-active drugs as inverse H<sub>1</sub> receptor agonists. *J Pharmacol Exp Ther* **322**:172–179.
- Bakker RA, Schoonus S, Smit MJ, Timmerman H, and Leurs R (2001) Histamine H<sub>1</sub>-receptor activation of NF- $\kappa$ B: roles for G $\beta$  $\gamma$  and G $\alpha_{q/11}$ -subunits in constitutive and agonist-mediated signaling. *Mol Pharmacol* **60**:1133–1142.
- Bakker RA, Wieland K, Timmerman H, and Leurs R (2000) Constitutive activity of the histamine H<sub>1</sub> receptor reveals inverse agonism of histamine H<sub>1</sub> receptor antagonists. *Eur J Pharmacol* **387**:R5–R7.
- Ballesteros J, Kitanovic S, Guarnieri F, Davies P, Fromme BJ, Konvicka K, Chi L, Millar RP, Davidson JS, Weinstein H, et al. (1998) Functional microdomains in G-protein-coupled receptors: the conserved arginine cage motif in the gonadotropin-releasing hormone receptor. *J Biol Chem* **273**:10445–10453.
- Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, Gether U, and Javitch JA (2001) Activation of the  $\beta_2$ -adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. *J Biol Chem* **276**:29171–29177.
- Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**:248–254.
- Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, et al. (2007) High-resolution crystal structure of an engineered human  $\beta_2$ -adrenergic G protein-coupled receptor. *Science*, in press.
- Claeysen S, Govaerts C, Lefort A, Van Sande J, Costagliola S, Pardo L, and Vassart G (2002) A conserved Asn in TM7 of the thyrotropin receptor is a common requirement for activation by both mutations and its natural agonist. *FEBS Lett* **517**:195–200.
- Flanagan CA (2005) A GPCR that is not “DRY”. *Mol Pharmacol* **68**:1–3.
- Fritze O, Filipek S, Kuksa V, Palczewski K, Hofmann KP, and Ernst OP (2003) Role of the conserved NPxxY(x)<sub>5,6</sub>F motif in the rhodopsin ground state and during activation. *Proc Natl Acad Sci U S A* **100**:2290–2295.
- Gether U, Asmar F, Meinild AK, and Rasmussen SGF (2002) Structural basis for activation of G-protein-coupled receptors. *Pharmacol Toxicol* **91**:304–312.
- Govaerts C, Lefort A, Costagliola S, Wodak S, Ballesteros JA, Pardo L, and Vassart G (2001) A conserved Asn in transmembrane helix 7 is an on/off switch in the activation of the thyrotropin receptor. *J Biol Chem* **276**:22991–22999.
- Han M, Lin SW, Minkova M, Smith SO, and Sakmar TP (1996) Functional interaction of transmembrane helices 3 and 6 in rhodopsin. Replacement of phenylalanine 261 by alanine causes reversion of phenotype of a glycine 121 replacement mutant. *J Biol Chem* **271**:32337–32342.
- Hill-Eubanks D, Burstein ES, Spalding TA, Brauner-Osborne H, and Brann MR (1996) Structure of a G-protein-coupling domain of a muscarinic receptor predicted by random saturation mutagenesis. *J Biol Chem* **271**:3058–3065.
- Hopkins AL and Groom CR (2002) The druggable genome. *Nat Rev Drug Discov* **1**:727–730.
- Jensen AA, Spalding TA, Burstein ES, Sheppard PO, O'Hara PJ, Brann MR, Krogs-gaard-Larsen P, and Bräuner-Osborne H (2000) Functional importance of the Ala<sup>116</sup>-Pro<sup>136</sup> region in the calcium-sensing receptor. Constitutive activity and inverse agonism in a family C G-protein-coupled receptor. *J Biol Chem* **275**:29547–29555.
- Jongejan A, Bruysters M, Ballesteros JA, Haaksma E, Bakker RA, Pardo L, and Leurs R (2005) Linking ligand binding to histamine H<sub>1</sub> receptor activation. *Nat Chem Biol* **1**:98–103.
- Kristiansen K (2004) Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. *Pharmacol Ther* **103**:21–80.
- Li B, Nowak NM, Kim SK, Jacobson KA, Bagheri A, Schmidt C, and Wess J (2005) Random mutagenesis of the M3 muscarinic acetylcholine receptor expressed in yeast: identification of second-site mutations that restore function to a coupling-deficient mutant M3 receptor. *J Biol Chem* **280**:5664–5675.
- Li J, Edwards PC, Burghammer M, Villa C, and Schertler GF (2004) Structure of bovine rhodopsin in a trigonal crystal form. *J Mol Biol* **343**:1409–1438.
- López-Rodríguez ML, Morcillo MJ, Fernández E, Benhamú B, Tejada I, Ayala D, Viso A, Campillo M, Pardo L, Delgado M, et al. (2005) Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT<sub>1A</sub>R agonists with selectivity over alpha1-adrenoceptors. *J Med Chem* **48**:2548–2558.
- Madabushi S, Gross AK, Philippi A, Meng EC, Wensel TG, and Lichtarge O (2004) Evolutionary trace of G protein-coupled receptors reveals clusters of residues that determine global and class-specific functions. *J Biol Chem* **279**:8126–8132.
- Mirzadegan T, Benko G, Filipek S, and Palczewski K (2003) Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. *Biochemistry* **42**:2759–2767.
- Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, and Shichida Y (2002) Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. *Proc Natl Acad Sci U S A* **99**:5982–5987.
- Pardo L, Deupi X, Dolker N, López-Rodríguez ML, and Campillo M (2007) The role of internal water molecules in the structure and function of the rhodopsin family of G protein-coupled receptors. *ChemBioChem* **8**:19–24.
- Proneth B, Xiang Z, Pogozheva ID, Litherland SA, Gorbatyuk OS, Shaw AM, Millard WJ, Mosberg HI, and Haskell-Luevano C (2006) Molecular mechanism of the constitutive activation of the L250Q human melanocortin-4 receptor polymorphism. *Chem Biol Drug Des* **67**:215–229.
- Ruprecht JJ, Mielke T, Vogel R, Villa C, and Schertler GF (2004) Electron crystallography reveals the structure of metarhodopsin I. *EMBO J* **23**:3609–3620.
- Scheer A, Fanelli F, Costa T, De Benedetti PG, and Cotecchia S (1996) Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. *EMBO J* **15**:3566–3578.
- Seifert R and Wieland T (2006) *GPCRs As Drug Targets: Analysis of Activation and Constitutive Activity*. Wiley-VCH Verlag GmbH, Weinheim, Germany.
- Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, and Roth BL (2002) Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. *J Biol Chem* **277**:11441–11449.
- Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, and Javitch JA (2002)  $\beta_2$  adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. *J Biol Chem* **277**:40989–40996.
- Smit MJ, Bakker RA, and Burstein ES (2002) G protein-coupled receptors and proliferative signaling. *Methods Enzymol* **343**:430–447.
- Smit MJ, Vischer HF, Bakker RA, Jongejan A, Timmerman H, Pardo L, and Leurs R (2007) Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity. *Annu Rev Pharmacol Toxicol* **47**:53–87.
- Spalding TA, Burstein ES, Wells JW, and Brann MR (1997) Constitutive activation of the M5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6. *Biochemistry* **36**:10109–10116.
- Urizar E, Claeysen S, Deupi X, Govaerts C, Costagliola S, Vassart G, and Pardo L (2005) An activation switch in the rhodopsin family of G protein-coupled receptors: the thyrotropin receptor. *J Biol Chem* **280**:17135–17141.
- Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, et al. (2001) 5-Hydroxytryptamine<sub>2A</sub> receptor inverse agonists as antipsychotics. *J Pharmacol Exp Ther* **299**:268–276.
- Wieland K, Laak AM, Smit MJ, Kühne R, Timmerman H, and Leurs R (1999) Mutational analysis of the antagonist-binding site of the histamine H<sub>1</sub> receptor. *J Biol Chem* **274**:29994–30000.
- Wu RL, Anthes JC, Kreutner W, Harris AG, and West RE, Jr. (2004) Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 receptor. *Int Arch Allergy Immunol* **135**:313–318.
- Xu W, Campillo M, Pardo L, de Riel JK, and Liu-Chen LY (2005) The seventh transmembrane domains of the delta and kappa opioid receptors have different accessibility patterns and interhelical interactions. *Biochemistry* **44**:16014–16025.
- Yu N, Atienza JM, Bernard J, Blanc S, Zhu J, Wang X, Xu X, and Abassi YA (2006) Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors. *Anal Chem* **78**:35–43.

**Address correspondence to:** Dr. R. Leurs, Leiden/Amsterdam Center for Drug Research, Department of Medicinal Chemistry, Vrije Universiteit Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands. E-mail: r.leurs@few.vu.nl